Latest Healthcare News

Epiminder says its $65.1 million cash balance can fund the DETECT study and next-generation Minder device into 2028, despite a higher quarterly operating outflow. The company also paid $3.5 million to major shareholder Cochlear for research and development during the quarter.

Nexsen is pursuing a second Group B Streptococcus device through a proposed FlashDx joint venture while upgrading StrepSure after interim clinical data shifted its US FDA submission target to early 2027. The diagnostics developer ended September with $3.56 million in cash, equivalent to about four quarters of funding at the latest operating cash-flow rate.

Lumos Diagnostics has expanded FebriDx deployment to 265 US healthcare sites across 29 states, while product revenue rose 224% in the first quarter. The commercial gains came alongside a US$4.7 million operating cash outflow, slower-than-planned paediatric study enrolment and a Hologic development timeline pushed to around June 2028.

Clarity Pharmaceuticals has completed planned recruitment for its 383-participant CLARIFY Phase III trial of 64Cu-SAR-bisPSMA, moving the diagnostic candidate into patient follow-up. Topline sensitivity and specificity data are expected in the first half of 2027 and could support a US FDA application.

Rhythm Biosciences has widened access to its ColoSTAT blood test, lifted quarterly revenue 64% and advanced reimbursement and NHS evaluation work. The progress sits alongside A$1.803 million in cash and an estimated 1.22 quarters of funding at the current operating burn.

Biome Australia has reported record pharmacy sell-through, further market-share gains and positive operating cash flow as it begins manufacturing Activated Probiotics domestically. The quarter also moved its China expansion and BMB18 clinical trial closer to key execution milestones.

Genetic Signatures has added a new AGM resolution seeking approval to issue up to 340.7 million shares and 129.7 million options under its proposed Microba merger. The all-scrip transaction remains non-binding and subject to further shareholder, court, regulatory and due diligence conditions.

Star Combo Pharma has completed a manufacturing expansion that doubles production capacity, but FY2026 revenue fell 15% and profit before tax dropped to $528,472. The company remains cash-backed and dividend-paying, while its next test is converting spare capacity into stronger OEM and Own Brands growth.

Hydration Pharmaceuticals is asking eligible shareholders for up to A$1.43 million in fresh capital as it funds the next phase of its turnaround. The non-renounceable offer comes with free options, but is neither underwritten nor subject to a minimum subscription.

Monash IVF Group’s underlying NPAT fell 41% to A$16.1 million in FY26, missing its recently reduced guidance as softer Australian IVF activity outweighed international growth. A second-half market-share recovery, lower planned capital spending and a new productivity program now carry the FY27 investment case.

CSL has been named as the defendant in a group proceeding filed in the Supreme Court of Victoria, covering investors who acquired certain securities between February 2025 and May 2026. The company denies liability and says it will vigorously defend allegations involving continuous disclosure and FY26 performance statements.

Orthocell’s flagship Remplir nerve-repair product gained ground in the US and Thailand during the September quarter, even as total revenue slipped from the June period. The company reported A$39 million in available funds and said it does not currently expect to raise additional capital.